Streetbeat News

Products Services

SHOT

Safety Shot, Inc. (NASDAQ:SHOT) has announced a strategic partnership with Mr. Checkout to expand its presence with independent retailers nationwide. This partnership aims to provide more access for consumers in diversified retail locations.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:23 pm

SNY

Sanofi's IMROZ Phase 3 study shows that Sarclisa combined with VRd reduces the risk of disease progression or death by 40% in newly diagnosed transplant-ineligible multiple myeloma patients. This is the first global Phase 3 study of anti-CD38 with VRd to improve progression-free survival (PFS) and show deep responses. The results were presented at ASCO and published in NEJM.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:21 pm

BLK

GBTC

Cryptocurrency markets have started the week in green, with notable gains in Bitcoin, Solana, and Dogecoin. Ethereum spot ETFs are anticipated to impact the market. Bitcoin's short liquidations peaked, and Wisconsin revealed owning Bitcoin through BlackRock and Grayscale ETFs.

Portfolio Pulse from Khyathi Dalal

June 03, 2024 | 8:20 pm

INGN

Inogen, Inc. (NASDAQ:INGN) published a study in the journal Pulmonary Therapy showing that portable oxygen concentrators (POCs) are associated with increased survival and cost-effectiveness compared to other long-term oxygen therapies. The study, using data from the French national healthcare system, analyzed over 244,000 patients and found that POCs improved survival rates and had similar healthcare resource use compared to stationary concentrators, compressed tanks, and liquid oxygen.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:20 pm

OABI

OmniAb announced the publication of a peer-reviewed paper in the Journal of Immunology. The paper discusses engineered chickens producing single-domain antibodies (sdAbs), which form the basis of OmniAb's novel transgenic chicken platform, OmnidAb™, launched in 2023.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:15 pm

MYGN

Myriad Genetics' Patient-Outcomes Study validating RiskScore as a clinical breast cancer risk assessment tool has been published in Medical Genetics and Genomics.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:13 pm

FGEN

REGN

FibroGen shares are trading higher after the company announced that the FDA cleared its Investigational New Drug FG-3165. Additionally, FibroGen has entered into a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate FG-3165 and FG-3175 in combination with LIBTAYO.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:10 pm

FGEN

REGN

FibroGen has entered into a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate its immuno-oncology assets, FG-3165 and FG-3175, in combination with Regeneron's anti-PD-1 therapy, LIBTAYO, in patients with solid tumors.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:09 pm

VCYT

Veracyte has reported new research utilizing its Afirma Genomic Resource for Intelligent Discovery (GRID) tool. This development could have implications for the company's future growth and market position.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:07 pm

ASND

Ascendis Pharma A/S (NASDAQ:ASND) presented new data and updated results from its Phase 1/2 IL-Believe Trial at ASCO 2024. The trial showed promising clinical responses in patients with anti-PD-1 refractory melanoma treated with TransCon IL-2 β/γ, both as monotherapy and in combination with TransCon TLR7/8 Agonist.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:05 pm